	US 11,987,612 B2
	Siglec-9 ECD fusion molecules
Spencer Liang, San Mateo, CA (US); Samuel Nalle, Pacifica, CA (US); Jeonghoon Sun, San Francisco, CA (US); Hua Long, San Carlos, CA (US); and Rashmi Bankoti, San Carlos, CA (US)
Assigned to Alector LLC, South San Francisco, CA (US)
Filed by Alector LLC, South San Francisco, CA (US)
Filed on Nov. 3, 2020, as Appl. No. 17/088,149.
Claims priority of provisional application 63/092,753, filed on Oct. 16, 2020.
Claims priority of provisional application 63/014,940, filed on Apr. 24, 2020.
Claims priority of provisional application 62/930,227, filed on Nov. 4, 2019.
Prior Publication US 2021/0284710 A1, Sep. 16, 2021
Int. Cl. C07K 14/705 (2006.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); C07K 16/28 (2006.01)

CPC C07K 14/70503 (2013.01) [A61K 38/1774 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); A61K 2039/545 (2013.01); C07K 2317/76 (2013.01); C07K 2319/30 (2013.01)]

20 Claims

1. An isolated fusion polypeptide comprising a Siglec-9 extracellular domain (ECD) comprising the amino acid sequence of SEQ ID NO: 78 and lacking the amino acid sequence of SEQ ID NO: 147, wherein the Siglec-9 ECD is joined at its C-terminus to an Fc domain.